Please Wait
Applying Filters...
menu
    • menu
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    MB 07803

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 882757-24-6, Mb-07803, Mb07803, Mb 07803, Gg81xf45c2, Ethyl 2-[[[5-[2-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-4-yl]furan-2-yl]-[(1-ethoxy-2-methyl-1-oxopropan-2-yl)amino]phosphoryl]amino]-2-methylpropanoate
    Molecular Formula
    C24H37N4O7PS
    Molecular Weight
    556.6  g/mol
    InChI Key
    CTKZZUXRWBCFEI-UHFFFAOYSA-N
    FDA UNII
    GG81XF45C2
    MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    ethyl 2-[[[5-[2-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-4-yl]furan-2-yl]-[(1-ethoxy-2-methyl-1-oxopropan-2-yl)amino]phosphoryl]amino]-2-methylpropanoate
    2.1.2 InChI
    InChI=1S/C24H37N4O7PS/c1-10-33-19(30)23(6,7)27-36(32,28-24(8,9)20(31)34-11-2)15-13-12-14(35-15)16-17(37-21(25)26-16)18(29)22(3,4)5/h12-13H,10-11H2,1-9H3,(H2,25,26)(H2,27,28,32)
    2.1.3 InChI Key
    CTKZZUXRWBCFEI-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCOC(=O)C(C)(C)NP(=O)(C1=CC=C(O1)C2=C(SC(=N2)N)C(=O)C(C)(C)C)NC(C)(C)C(=O)OCC
    2.2 Other Identifiers
    2.2.1 UNII
    GG81XF45C2
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 882757-24-6

    2. Mb-07803

    3. Mb07803

    4. Mb 07803

    5. Gg81xf45c2

    6. Ethyl 2-[[[5-[2-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-4-yl]furan-2-yl]-[(1-ethoxy-2-methyl-1-oxopropan-2-yl)amino]phosphoryl]amino]-2-methylpropanoate

    7. Unii-gg81xf45c2

    8. Chembl4297400

    9. Schembl14255484

    10. Dtxsid90236932

    11. Act04837

    12. Db05053

    13. Sb17400

    14. Vk-0612

    15. Hy-16309

    16. Cs-0006389

    17. Q27279094

    18. Alanine, N,n'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methyl-, 1,1''-diethyl Ester

    19. N,n'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methylalanine) Diethyl Ester

    2.4 Create Date
    2008-04-28
    3 Chemical and Physical Properties
    Molecular Weight 556.6 g/mol
    Molecular Formula C24H37N4O7PS
    XLogP33.4
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count14
    Exact Mass556.21205770 g/mol
    Monoisotopic Mass556.21205770 g/mol
    Topological Polar Surface Area191 Ų
    Heavy Atom Count37
    Formal Charge0
    Complexity872
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in diabetes mellitus type 2.

    5 Pharmacology and Biochemistry
    5.1 Mechanism of Action

    MB07803 is a selective inhibitor of fructose-1, 6-bisphosphatase (FBPase), a regulatory enzyme in the pathway responsible for the production of glucose in the liver, known as the gluconeogenesis pathway. By specifically inhibiting this pathway, liver glucose production should be reduced and blood sugar levels decreased in patients with diabetes, independent of insulin levels and body weight.